Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized open-label phase II study of immune checkpoint inhibitors plus axitinib in untreated unresectable locally advanced or metastatic renal cell carcinoma
CTR20230315Phase 2Active
- Sponsor
- Roche
- Start
- May 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in clear cell renal cell carcinoma (ccRCC) comparing tiragolumab + axitinib, RO7247669 (tobemstomig) + axitinib and Keytruda (pembrolizumab) + axitinib (3 arms). Primary endpoints: Progression-free survival (PFS) and Incidence and severity of adverse events. Started May 2023; status: active.
02
Drugs
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on CTR20230315.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230315.